Cargando…
The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 16...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043326/ https://www.ncbi.nlm.nih.gov/pubmed/36998463 http://dx.doi.org/10.3389/fonc.2023.1109980 |
_version_ | 1784913121396129792 |
---|---|
author | Ding, Yezhou Feng, Mingyang Ma, Di Zhao, Gangde Wang, Xiaolin An, Baoyan Xu, Yumin Lou, Shike Lin, Lanyi Xie, Qing Liu, Kehui Bao, Shisan Wang, Hui |
author_facet | Ding, Yezhou Feng, Mingyang Ma, Di Zhao, Gangde Wang, Xiaolin An, Baoyan Xu, Yumin Lou, Shike Lin, Lanyi Xie, Qing Liu, Kehui Bao, Shisan Wang, Hui |
author_sort | Ding, Yezhou |
collection | PubMed |
description | BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients. RESULTS: The average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05). CONCLUSIONS: It was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs. |
format | Online Article Text |
id | pubmed-10043326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100433262023-03-29 The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China Ding, Yezhou Feng, Mingyang Ma, Di Zhao, Gangde Wang, Xiaolin An, Baoyan Xu, Yumin Lou, Shike Lin, Lanyi Xie, Qing Liu, Kehui Bao, Shisan Wang, Hui Front Oncol Oncology BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients. RESULTS: The average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05). CONCLUSIONS: It was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043326/ /pubmed/36998463 http://dx.doi.org/10.3389/fonc.2023.1109980 Text en Copyright © 2023 Ding, Feng, Ma, Zhao, Wang, An, Xu, Lou, Lin, Xie, Liu, Bao and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ding, Yezhou Feng, Mingyang Ma, Di Zhao, Gangde Wang, Xiaolin An, Baoyan Xu, Yumin Lou, Shike Lin, Lanyi Xie, Qing Liu, Kehui Bao, Shisan Wang, Hui The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title_full | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title_fullStr | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title_full_unstemmed | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title_short | The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China |
title_sort | 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from china |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043326/ https://www.ncbi.nlm.nih.gov/pubmed/36998463 http://dx.doi.org/10.3389/fonc.2023.1109980 |
work_keys_str_mv | AT dingyezhou the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT fengmingyang the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT madi the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT zhaogangde the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT wangxiaolin the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT anbaoyan the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xuyumin the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT loushike the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT linlanyi the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xieqing the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT liukehui the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT baoshisan the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT wanghui the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT dingyezhou 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT fengmingyang 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT madi 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT zhaogangde 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT wangxiaolin 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT anbaoyan 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xuyumin 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT loushike 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT linlanyi 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT xieqing 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT liukehui 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT baoshisan 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina AT wanghui 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina |